- Home
- GILD vs STX Comparison
GILD vs STX Comparison
Compare GILD & STX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | STX |
|---|---|---|
| Founded | 1987 | 1978 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.6B | 209.5B |
| IPO Year | 2003 | 2002 |
Fundamental Metrics
Financial Performance| Metric | GILD | STX |
|---|---|---|
| Price | $147.32 | $937.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 25 |
| Target Price | $158.65 | ★ $1,125.00 |
| AVG Volume (30 Days) | ★ 4.6M | 3.2M |
| Earning Date | 10-29-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.20% | 0.32% |
| EPS Growth | ★ 1684.21 | 105.32 |
| EPS | N/A | ★ 13.90 |
| Revenue | ★ $24,689,000,000.00 | $7,384,000,000.00 |
| Revenue This Year | $4.28 | $54.04 |
| Revenue Next Year | $6.45 | $33.65 |
| P/E Ratio | ★ N/A | $66.69 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $109.66 | $209.00 |
| 52 Week High | $157.29 | $1,145.00 |
Technical Indicators
Market Signals| Indicator | GILD | STX |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 57.21 |
| Support Level | $142.99 | $774.26 |
| Resistance Level | $152.04 | $937.61 |
| Average True Range (ATR) | 3.32 | 41.50 |
| MACD | -0.45 | 7.70 |
| Stochastic Oscillator | 52.89 | 83.71 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.